CN114085845B - Tobacco nicotine metabolism related gene and application thereof - Google Patents
Tobacco nicotine metabolism related gene and application thereof Download PDFInfo
- Publication number
- CN114085845B CN114085845B CN202111388043.8A CN202111388043A CN114085845B CN 114085845 B CN114085845 B CN 114085845B CN 202111388043 A CN202111388043 A CN 202111388043A CN 114085845 B CN114085845 B CN 114085845B
- Authority
- CN
- China
- Prior art keywords
- gene
- tobacco
- temperature
- sgrna
- nicotine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 71
- 229960002715 nicotine Drugs 0.000 title claims abstract description 61
- 235000002637 Nicotiana tabacum Nutrition 0.000 title claims abstract description 57
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 54
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 230000004060 metabolic process Effects 0.000 title claims abstract description 22
- 244000061176 Nicotiana tabacum Species 0.000 title description 6
- 241000208125 Nicotiana Species 0.000 claims abstract description 53
- 108091033409 CRISPR Proteins 0.000 claims abstract description 34
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 20
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000013604 expression vector Substances 0.000 claims abstract description 11
- 241000589158 Agrobacterium Species 0.000 claims abstract description 8
- 206010020649 Hyperkeratosis Diseases 0.000 claims abstract description 7
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims abstract description 7
- 241000196324 Embryophyta Species 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 10
- 229930013930 alkaloid Natural products 0.000 claims description 9
- 238000000137 annealing Methods 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 5
- 244000020518 Carthamus tinctorius Species 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 238000001976 enzyme digestion Methods 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 3
- 238000004817 gas chromatography Methods 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 238000000691 measurement method Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 241000589155 Agrobacterium tumefaciens Species 0.000 claims description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 claims description 2
- 102000003960 Ligases Human genes 0.000 claims description 2
- 108090000364 Ligases Proteins 0.000 claims description 2
- 230000005200 bud stage Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 238000011160 research Methods 0.000 abstract description 8
- 238000012258 culturing Methods 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 2
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 2
- PWHVEHULNLETOV-UHFFFAOYSA-N Nic-1 Natural products C12OC2C2(O)CC=CC(=O)C2(C)C(CCC2=C3)C1C2=CC=C3C(C)C1OC(O)C2(C)OC2(C)C1 PWHVEHULNLETOV-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- FBOFHVFMPNNIKN-UHFFFAOYSA-N dimethylquinoline Natural products C1=CC=C2N=C(C)C(C)=CC2=C1 FBOFHVFMPNNIKN-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- GWWNCLHJCFNTJA-UHFFFAOYSA-N nicandrenone-2 Natural products C12OC2C2(O)CC=CC(=O)C2(C)C(CCC23C)C1C3CCC2(O)C(C)C1OC(O)C2(C)OC2(C)C1 GWWNCLHJCFNTJA-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MYKUKUCHPMASKF-VIFPVBQESA-N (S)-nornicotine Chemical compound C1CCN[C@@H]1C1=CC=CN=C1 MYKUKUCHPMASKF-VIFPVBQESA-N 0.000 description 1
- HXUVTXPOZRFMOY-NSHDSACASA-N 2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]acetic acid Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 HXUVTXPOZRFMOY-NSHDSACASA-N 0.000 description 1
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 1
- ROFVEXUMMXZLPA-WQPYEJCJSA-N 3,4-dideuterio-2-pyridin-2-ylpyridine Chemical compound [2H]C1=C(C(=NC=C1)C1=NC=CC=C1)[2H] ROFVEXUMMXZLPA-WQPYEJCJSA-N 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- ODWSTKXGQGYHSH-FXQIFTODSA-N Ala-Arg-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O ODWSTKXGQGYHSH-FXQIFTODSA-N 0.000 description 1
- GSCLWXDNIMNIJE-ZLUOBGJFSA-N Ala-Asp-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GSCLWXDNIMNIJE-ZLUOBGJFSA-N 0.000 description 1
- IKKVASZHTMKJIR-ZKWXMUAHSA-N Ala-Asp-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IKKVASZHTMKJIR-ZKWXMUAHSA-N 0.000 description 1
- IFTVANMRTIHKML-WDSKDSINSA-N Ala-Gln-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O IFTVANMRTIHKML-WDSKDSINSA-N 0.000 description 1
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 1
- NYDBKUNVSALYPX-NAKRPEOUSA-N Ala-Ile-Arg Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NYDBKUNVSALYPX-NAKRPEOUSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- OTUQSEPIIVBYEM-IHRRRGAJSA-N Arg-Asn-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OTUQSEPIIVBYEM-IHRRRGAJSA-N 0.000 description 1
- YUGFLWBWAJFGKY-BQBZGAKWSA-N Arg-Cys-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O YUGFLWBWAJFGKY-BQBZGAKWSA-N 0.000 description 1
- HAVKMRGWNXMCDR-STQMWFEESA-N Arg-Gly-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HAVKMRGWNXMCDR-STQMWFEESA-N 0.000 description 1
- JTZUZBADHGISJD-SRVKXCTJSA-N Arg-His-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JTZUZBADHGISJD-SRVKXCTJSA-N 0.000 description 1
- NGTYEHIRESTSRX-UWVGGRQHSA-N Arg-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NGTYEHIRESTSRX-UWVGGRQHSA-N 0.000 description 1
- XUGATJVGQUGQKY-ULQDDVLXSA-N Arg-Lys-Phe Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XUGATJVGQUGQKY-ULQDDVLXSA-N 0.000 description 1
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 1
- FOWOZYAWODIRFZ-JYJNAYRXSA-N Arg-Tyr-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCN=C(N)N)N FOWOZYAWODIRFZ-JYJNAYRXSA-N 0.000 description 1
- XYOVHPDDWCEUDY-CIUDSAMLSA-N Asn-Ala-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O XYOVHPDDWCEUDY-CIUDSAMLSA-N 0.000 description 1
- XWGJDUSDTRPQRK-ZLUOBGJFSA-N Asn-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O XWGJDUSDTRPQRK-ZLUOBGJFSA-N 0.000 description 1
- BHQQRVARKXWXPP-ACZMJKKPSA-N Asn-Asp-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N BHQQRVARKXWXPP-ACZMJKKPSA-N 0.000 description 1
- GLWFAWNYGWBMOC-SRVKXCTJSA-N Asn-Leu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GLWFAWNYGWBMOC-SRVKXCTJSA-N 0.000 description 1
- JEEFEQCRXKPQHC-KKUMJFAQSA-N Asn-Leu-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JEEFEQCRXKPQHC-KKUMJFAQSA-N 0.000 description 1
- PBFXCUOEGVJTMV-QXEWZRGKSA-N Asn-Met-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O PBFXCUOEGVJTMV-QXEWZRGKSA-N 0.000 description 1
- KBQOUDLMWYWXNP-YDHLFZDLSA-N Asn-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KBQOUDLMWYWXNP-YDHLFZDLSA-N 0.000 description 1
- IXIWEFWRKIUMQX-DCAQKATOSA-N Asp-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O IXIWEFWRKIUMQX-DCAQKATOSA-N 0.000 description 1
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 description 1
- VZNOVQKGJQJOCS-SRVKXCTJSA-N Asp-Asp-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VZNOVQKGJQJOCS-SRVKXCTJSA-N 0.000 description 1
- BPTFNDRZKBFMTH-DCAQKATOSA-N Asp-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N BPTFNDRZKBFMTH-DCAQKATOSA-N 0.000 description 1
- YFGUZQQCSDZRBN-DCAQKATOSA-N Asp-Pro-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YFGUZQQCSDZRBN-DCAQKATOSA-N 0.000 description 1
- GGRSYTUJHAZTFN-IHRRRGAJSA-N Asp-Pro-Tyr Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O GGRSYTUJHAZTFN-IHRRRGAJSA-N 0.000 description 1
- BRRPVTUFESPTCP-ACZMJKKPSA-N Asp-Ser-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O BRRPVTUFESPTCP-ACZMJKKPSA-N 0.000 description 1
- BYLPQJAWXJWUCJ-YDHLFZDLSA-N Asp-Tyr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O BYLPQJAWXJWUCJ-YDHLFZDLSA-N 0.000 description 1
- NLCZGISONIGRQP-DCAQKATOSA-N Cys-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N NLCZGISONIGRQP-DCAQKATOSA-N 0.000 description 1
- VPQZSNQICFCCSO-BJDJZHNGSA-N Cys-Leu-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VPQZSNQICFCCSO-BJDJZHNGSA-N 0.000 description 1
- BNCKELUXXUYRNY-GUBZILKMSA-N Cys-Lys-Glu Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N BNCKELUXXUYRNY-GUBZILKMSA-N 0.000 description 1
- 101100268840 Danio rerio chrna1 gene Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- LLRJEFPKIIBGJP-DCAQKATOSA-N Gln-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N LLRJEFPKIIBGJP-DCAQKATOSA-N 0.000 description 1
- SXFPZRRVWSUYII-KBIXCLLPSA-N Gln-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N SXFPZRRVWSUYII-KBIXCLLPSA-N 0.000 description 1
- JPHYJQHPILOKHC-ACZMJKKPSA-N Glu-Asp-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JPHYJQHPILOKHC-ACZMJKKPSA-N 0.000 description 1
- QIQABBIDHGQXGA-ZPFDUUQYSA-N Glu-Ile-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QIQABBIDHGQXGA-ZPFDUUQYSA-N 0.000 description 1
- SWRVAQHFBRZVNX-GUBZILKMSA-N Glu-Lys-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O SWRVAQHFBRZVNX-GUBZILKMSA-N 0.000 description 1
- BPLNJYHNAJVLRT-ACZMJKKPSA-N Glu-Ser-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O BPLNJYHNAJVLRT-ACZMJKKPSA-N 0.000 description 1
- HZISRJBYZAODRV-XQXXSGGOSA-N Glu-Thr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O HZISRJBYZAODRV-XQXXSGGOSA-N 0.000 description 1
- CQGBSALYGOXQPE-HTUGSXCWSA-N Glu-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O CQGBSALYGOXQPE-HTUGSXCWSA-N 0.000 description 1
- JVZLZVJTIXVIHK-SXNHZJKMSA-N Glu-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N JVZLZVJTIXVIHK-SXNHZJKMSA-N 0.000 description 1
- VIPDPMHGICREIS-GVXVVHGQSA-N Glu-Val-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VIPDPMHGICREIS-GVXVVHGQSA-N 0.000 description 1
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 1
- QIZJOTQTCAGKPU-KWQFWETISA-N Gly-Ala-Tyr Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 QIZJOTQTCAGKPU-KWQFWETISA-N 0.000 description 1
- XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 1
- GNBMOZPQUXTCRW-STQMWFEESA-N Gly-Asn-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)CN)C(O)=O)=CNC2=C1 GNBMOZPQUXTCRW-STQMWFEESA-N 0.000 description 1
- FIQQRCFQXGLOSZ-WDSKDSINSA-N Gly-Glu-Asp Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FIQQRCFQXGLOSZ-WDSKDSINSA-N 0.000 description 1
- NTOWAXLMQFKJPT-YUMQZZPRSA-N Gly-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CN NTOWAXLMQFKJPT-YUMQZZPRSA-N 0.000 description 1
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 1
- LPCKHUXOGVNZRS-YUMQZZPRSA-N Gly-His-Ser Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O LPCKHUXOGVNZRS-YUMQZZPRSA-N 0.000 description 1
- COVXELOAORHTND-LSJOCFKGSA-N Gly-Ile-Val Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O COVXELOAORHTND-LSJOCFKGSA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
- FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 1
- YHYDTTUSJXGTQK-UWVGGRQHSA-N Gly-Met-Leu Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(C)C)C(O)=O YHYDTTUSJXGTQK-UWVGGRQHSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- XJQDHFMUUBRCGA-KKUMJFAQSA-N His-Asn-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XJQDHFMUUBRCGA-KKUMJFAQSA-N 0.000 description 1
- VOKCBYNCZVSILJ-KKUMJFAQSA-N His-Asn-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CN=CN2)N)O VOKCBYNCZVSILJ-KKUMJFAQSA-N 0.000 description 1
- MDBYBTWRMOAJAY-NHCYSSNCSA-N His-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MDBYBTWRMOAJAY-NHCYSSNCSA-N 0.000 description 1
- ORERHHPZDDEMSC-VGDYDELISA-N His-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N ORERHHPZDDEMSC-VGDYDELISA-N 0.000 description 1
- HYWZHNUGAYVEEW-KKUMJFAQSA-N His-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N HYWZHNUGAYVEEW-KKUMJFAQSA-N 0.000 description 1
- LEDRIAHEWDJRMF-CFMVVWHZSA-N Ile-Asn-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LEDRIAHEWDJRMF-CFMVVWHZSA-N 0.000 description 1
- HTDRTKMNJRRYOJ-SIUGBPQLSA-N Ile-Gln-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HTDRTKMNJRRYOJ-SIUGBPQLSA-N 0.000 description 1
- UBHUJPVCJHPSEU-GRLWGSQLSA-N Ile-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N UBHUJPVCJHPSEU-GRLWGSQLSA-N 0.000 description 1
- TWPSALMCEHCIOY-YTFOTSKYSA-N Ile-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O)N TWPSALMCEHCIOY-YTFOTSKYSA-N 0.000 description 1
- KTTMFLSBTNBAHL-MXAVVETBSA-N Ile-Phe-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N KTTMFLSBTNBAHL-MXAVVETBSA-N 0.000 description 1
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- MJOZZTKJZQFKDK-GUBZILKMSA-N Leu-Ala-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(N)=O MJOZZTKJZQFKDK-GUBZILKMSA-N 0.000 description 1
- VKOAHIRLIUESLU-ULQDDVLXSA-N Leu-Arg-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O VKOAHIRLIUESLU-ULQDDVLXSA-N 0.000 description 1
- XVSJMWYYLHPDKY-DCAQKATOSA-N Leu-Asp-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O XVSJMWYYLHPDKY-DCAQKATOSA-N 0.000 description 1
- DLCXCECTCPKKCD-GUBZILKMSA-N Leu-Gln-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DLCXCECTCPKKCD-GUBZILKMSA-N 0.000 description 1
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 1
- SEMUSFOBZGKBGW-YTFOTSKYSA-N Leu-Ile-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SEMUSFOBZGKBGW-YTFOTSKYSA-N 0.000 description 1
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 1
- MJWVXZABPOKJJF-ACRUOGEOSA-N Leu-Phe-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MJWVXZABPOKJJF-ACRUOGEOSA-N 0.000 description 1
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 1
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 1
- XOEDPXDZJHBQIX-ULQDDVLXSA-N Leu-Val-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XOEDPXDZJHBQIX-ULQDDVLXSA-N 0.000 description 1
- WQWZXKWOEVSGQM-DCAQKATOSA-N Lys-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN WQWZXKWOEVSGQM-DCAQKATOSA-N 0.000 description 1
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 1
- NNKLKUUGESXCBS-KBPBESRZSA-N Lys-Gly-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NNKLKUUGESXCBS-KBPBESRZSA-N 0.000 description 1
- MXMDJEJWERYPMO-XUXIUFHCSA-N Lys-Ile-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MXMDJEJWERYPMO-XUXIUFHCSA-N 0.000 description 1
- WAIHHELKYSFIQN-XUXIUFHCSA-N Lys-Ile-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O WAIHHELKYSFIQN-XUXIUFHCSA-N 0.000 description 1
- YXPJCVNIDDKGOE-MELADBBJSA-N Lys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)O YXPJCVNIDDKGOE-MELADBBJSA-N 0.000 description 1
- SQRLLZAQNOQCEG-KKUMJFAQSA-N Lys-Tyr-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 SQRLLZAQNOQCEG-KKUMJFAQSA-N 0.000 description 1
- WGBMNLCRYKSWAR-DCAQKATOSA-N Met-Asp-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN WGBMNLCRYKSWAR-DCAQKATOSA-N 0.000 description 1
- AFVOKRHYSSFPHC-STECZYCISA-N Met-Ile-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFVOKRHYSSFPHC-STECZYCISA-N 0.000 description 1
- NTYQUVLERIHPMU-HRCADAONSA-N Met-Phe-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N NTYQUVLERIHPMU-HRCADAONSA-N 0.000 description 1
- WXXNVZMWHOLNRJ-AVGNSLFASA-N Met-Pro-Lys Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O WXXNVZMWHOLNRJ-AVGNSLFASA-N 0.000 description 1
- NDJSSFWDYDUQID-YTWAJWBKSA-N Met-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N)O NDJSSFWDYDUQID-YTWAJWBKSA-N 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 241000208134 Nicotiana rustica Species 0.000 description 1
- MYKUKUCHPMASKF-UHFFFAOYSA-N Nornicotine Natural products C1CCNC1C1=CC=CN=C1 MYKUKUCHPMASKF-UHFFFAOYSA-N 0.000 description 1
- 241000192656 Nostoc Species 0.000 description 1
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 description 1
- CZQZSMJXFGGBHM-KKUMJFAQSA-N Phe-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O CZQZSMJXFGGBHM-KKUMJFAQSA-N 0.000 description 1
- GZGPMBKUJDRICD-ULQDDVLXSA-N Phe-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O GZGPMBKUJDRICD-ULQDDVLXSA-N 0.000 description 1
- UNBFGVQVQGXXCK-KKUMJFAQSA-N Phe-Ser-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O UNBFGVQVQGXXCK-KKUMJFAQSA-N 0.000 description 1
- 108020005089 Plant RNA Proteins 0.000 description 1
- APKRGYLBSCWJJP-FXQIFTODSA-N Pro-Ala-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O APKRGYLBSCWJJP-FXQIFTODSA-N 0.000 description 1
- NXEYSLRNNPWCRN-SRVKXCTJSA-N Pro-Glu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXEYSLRNNPWCRN-SRVKXCTJSA-N 0.000 description 1
- WFIVLLFYUZZWOD-RHYQMDGZSA-N Pro-Lys-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WFIVLLFYUZZWOD-RHYQMDGZSA-N 0.000 description 1
- RPLMFKUKFZOTER-AVGNSLFASA-N Pro-Met-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CCCN1 RPLMFKUKFZOTER-AVGNSLFASA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- JDJMFMVVJHLWDP-UNQGMJICSA-N Pro-Thr-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JDJMFMVVJHLWDP-UNQGMJICSA-N 0.000 description 1
- RMJZWERKFFNNNS-XGEHTFHBSA-N Pro-Thr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMJZWERKFFNNNS-XGEHTFHBSA-N 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- VAIZFHMTBFYJIA-ACZMJKKPSA-N Ser-Asp-Gln Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O VAIZFHMTBFYJIA-ACZMJKKPSA-N 0.000 description 1
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 1
- MQQBBLVOUUJKLH-HJPIBITLSA-N Ser-Ile-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MQQBBLVOUUJKLH-HJPIBITLSA-N 0.000 description 1
- BYCVMHKULKRVPV-GUBZILKMSA-N Ser-Lys-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYCVMHKULKRVPV-GUBZILKMSA-N 0.000 description 1
- KJKQUQXDEKMPDK-FXQIFTODSA-N Ser-Met-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O KJKQUQXDEKMPDK-FXQIFTODSA-N 0.000 description 1
- NUEHQDHDLDXCRU-GUBZILKMSA-N Ser-Pro-Arg Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NUEHQDHDLDXCRU-GUBZILKMSA-N 0.000 description 1
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- NFMPFBCXABPALN-OWLDWWDNSA-N Thr-Ala-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O NFMPFBCXABPALN-OWLDWWDNSA-N 0.000 description 1
- GARULAKWZGFIKC-RWRJDSDZSA-N Thr-Gln-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GARULAKWZGFIKC-RWRJDSDZSA-N 0.000 description 1
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 1
- NIEWSKWFURSECR-FOHZUACHSA-N Thr-Gly-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O NIEWSKWFURSECR-FOHZUACHSA-N 0.000 description 1
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 1
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 1
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 1
- TZQWJCGVCIJDMU-HEIBUPTGSA-N Thr-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)O)N)O TZQWJCGVCIJDMU-HEIBUPTGSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- JNKAYADBODLPMQ-HSHDSVGOSA-N Thr-Trp-Val Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)[C@@H](C)O)=CNC2=C1 JNKAYADBODLPMQ-HSHDSVGOSA-N 0.000 description 1
- AKHDFZHUPGVFEJ-YEPSODPASA-N Thr-Val-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AKHDFZHUPGVFEJ-YEPSODPASA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- IXEGQBJZDIRRIV-QEJZJMRPSA-N Trp-Asn-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IXEGQBJZDIRRIV-QEJZJMRPSA-N 0.000 description 1
- FBVGQXJIXFZKSQ-GMVOTWDCSA-N Tyr-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N FBVGQXJIXFZKSQ-GMVOTWDCSA-N 0.000 description 1
- ZNFPUOSTMUMUDR-JRQIVUDYSA-N Tyr-Asn-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZNFPUOSTMUMUDR-JRQIVUDYSA-N 0.000 description 1
- HVHJYXDXRIWELT-RYUDHWBXSA-N Tyr-Glu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O HVHJYXDXRIWELT-RYUDHWBXSA-N 0.000 description 1
- CDHQEOXPWBDFPL-QWRGUYRKSA-N Tyr-Gly-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDHQEOXPWBDFPL-QWRGUYRKSA-N 0.000 description 1
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 1
- OGPKMBOPMDTEDM-IHRRRGAJSA-N Tyr-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N OGPKMBOPMDTEDM-IHRRRGAJSA-N 0.000 description 1
- SCZJKZLFSSPJDP-ACRUOGEOSA-N Tyr-Phe-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O SCZJKZLFSSPJDP-ACRUOGEOSA-N 0.000 description 1
- ISERLACIZUGCDX-ZKWXMUAHSA-N Val-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N ISERLACIZUGCDX-ZKWXMUAHSA-N 0.000 description 1
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 1
- BRPKEERLGYNCNC-NHCYSSNCSA-N Val-Glu-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N BRPKEERLGYNCNC-NHCYSSNCSA-N 0.000 description 1
- ROLGIBMFNMZANA-GVXVVHGQSA-N Val-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N ROLGIBMFNMZANA-GVXVVHGQSA-N 0.000 description 1
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 1
- JMCOXFSCTGKLLB-FKBYEOEOSA-N Val-Phe-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N JMCOXFSCTGKLLB-FKBYEOEOSA-N 0.000 description 1
- QZKVWWIUSQGWMY-IHRRRGAJSA-N Val-Ser-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QZKVWWIUSQGWMY-IHRRRGAJSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- UJMCYJKPDFQLHX-XGEHTFHBSA-N Val-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N)O UJMCYJKPDFQLHX-XGEHTFHBSA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- PDASTHRLDFOZMG-JYJNAYRXSA-N Val-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CC=C(O)C=C1 PDASTHRLDFOZMG-JYJNAYRXSA-N 0.000 description 1
- 241001002356 Valeriana edulis Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000009418 agronomic effect Effects 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010078114 alanyl-tryptophyl-alanine Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000013373 clone screening Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 108010004073 cysteinylcysteine Proteins 0.000 description 1
- 108010009297 diglycyl-histidine Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010028188 glycyl-histidyl-serine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 108010060857 isoleucyl-valyl-tyrosine Proteins 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108010064486 phenylalanyl-leucyl-valine Proteins 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 1
- 108010078580 tyrosylleucine Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
The invention discloses a gene related to tobacco nicotine metabolism and application thereof, wherein the gene is an NtLNP2 gene, the sequence of the gene is SEQ ID No.1, and after the sequence of the gene is translated, the coded protein sequence of the gene is SEQ ID No.2. A method of knocking out a gene associated with tobacco nicotine metabolism using a CRISPR/Cas9 system, comprising the steps of: (1) Designing a sgRNA guide sequence and constructing a sgRNA expression vector; (2) introducing an expression vector into agrobacterium; (3) infecting the callus; (4) And (3) detecting the nicotine content of the leaves in the bud period of the homozygous knockout material of the NtLNP2 gene by using GC-MS. The gene and the method provide genetic materials and theoretical basis for the functional research of the tobacco nicotine metabolism gene and the cultivation research of new varieties of low-nicotine tobacco.
Description
Technical Field
The invention relates to the technical field of plant genetic engineering, in particular to a gene related to tobacco nicotine metabolism and application thereof.
Background
Alkaloids are important chemical components of plants of the genus Nicotiana (Nicotiana), with nicotine being the predominant alkaloid, accounting for more than about 90%. The nicotine is a main physiological active ingredient in tobacco leaves, and the content of the nicotine determines the physiological strength of the tobacco leaves and is also a main ingredient for causing addiction of tobacco products. In order to reduce the rate of smoking, the world health organization recommends reducing the nicotine content in the cut tobacco of cigarettes to below 0.4 mg/g. Therefore, the feasibility of low-nicotine-content tobacco leaf production technology and the influence on tobacco leaf quality and consumer experience have become research hotspots in the international tobacco community in recent years.
The nicotine content of tobacco leaves is fundamentally controlled by genetic factors, but is strongly influenced by measures such as ecology, agriculture and the like. The current low-nicotine tobacco variety cultivation comprises conventional breeding, genetic engineering and the like. Certain low-nicotine materials exist in tobacco gene resources, but the materials are generally poor in agronomic characters and have no cultivation and utilization values. Legg et al found that alkaloids were controlled by two independent genetic loci, nic1 and Nic2. Researchers have also grown cured tobacco and dark air cured tobacco lines with different Nic1.Nic2 obvious recessive combinations by crossing, backcrossing and diploid cultures. In addition, nicotine can be demethylated by nicotine demethylase to convert it to nornicotine, and the cultivation of a nicotine conversion line having nicotine demethylase activity is an alternative route to lower nicotine tobacco. The key gene for synthesizing nicotine can be inhibited or knocked out by molecular means, so that the synthesis of nicotine can be effectively reduced, and the nicotine content of tobacco leaves can be reduced to an extremely low level.
Through extensive researches for over 20 years, the metabolic process of alkaloid synthesis is clearer, and particularly key regulatory sites and control genes are gradually disclosed and recognized, which provides possibility for effectively regulating alkaloid synthesis, transportation and accumulation through genetic engineering and becomes a main way for controlling the nicotine content of tobacco leaves and creating ultra-low nicotine materials in recent years. At present, research on nicotine genetic engineering by using key genes and molecular regulatory mechanisms of alkaloid synthesis is mainly focused on PMT genes, MPO genes, QPT genes, A662 enzyme genes, BBL genes, nicotine root and leaf transport genes and the like.
Disclosure of Invention
The invention aims to solve the technical problem of providing a gene related to tobacco nicotine metabolism and application thereof, and provides genetic materials and theoretical basis for researching the functions of the tobacco nicotine metabolism gene and directionally improving new varieties of low-nicotine tobacco.
The technical problems to be solved by the invention are realized by the following technical scheme:
a gene related to tobacco nicotine metabolism, which is a NtLNP2 gene, the sequence of which is SEQ ID No.1.
Preferably, the sequence of the gene is translated, and the encoded protein sequence is SEQ ID NO.2.
A method of knocking out a gene associated with tobacco nicotine metabolism, the gene associated with tobacco nicotine metabolism being the NtLNP2 gene described above, using a CRISPR/Cas9 system, the method comprising the steps of:
(1) Designing a sgRNA guide sequence and constructing a sgRNA expression vector;
(2) Introducing an expression vector into agrobacterium;
(3) Infection of callus;
(4) And (3) detecting the nicotine content of the leaves in the bud period of the homozygous knockout material of the NtLNP2 gene by using GC-MS.
Preferably, in step (1), the CRISPR/Cas9 system employs a sgRNA sequence of GAGACCTGCAGATCTACCCGCGG, and the sgRNA sequence employs a primer sequence of:
the upstream primer sgRNA-F: GATTGGAGACCTGCAGATCTACCCG;
the downstream primer sgRNA-R: AAACCGGGTAGATCTGCAGGTCTCC.
Preferably, the step (1) specifically comprises:
designing an sgRNA guide sequence, annealing an upstream primer sgRNA-F and a downstream primer sgRNA-R to form a double chain, and performing restriction enzyme digestion on a CRISPR/Cas9 vector pORE-Cas9 by using restriction enzyme BsaI-HF; connecting the double-stranded product formed by annealing with the carrier skeleton cut by enzyme by using T4 ligase; and (3) converting the connection product into competent cells of escherichia coli, detecting to obtain positive clones, and extracting the recombinant plasmid to obtain the CRISPR-Cas9 expression vector.
Preferably, the step (3) specifically comprises:
and soaking the infected tobacco leaf disc with agrobacterium tumefaciens LBA4404 bacterial liquid carrying the CRISPR/Cas9-sgRNA expression vector, and obtaining the T0 generation editing plant seeds and the T1 generation seeds.
Preferably, the chromatographic conditions in step (4) are:
the gas chromatography conditions were: chromatographic column: DB-35MS or equivalent column effect capillary chromatographic column; the specification is as follows: 30mm by 0.25m; sample introduction temperature: 250 ℃; column flow rate: 1.0mL/min; nicotine sample injection volume: 1.0L, split sample introduction, and split ratio of 40:1; other alkaloid sample injection volumes: 2.0L, split sample introduction, wherein the split ratio is 10:1; heating program: the initial temperature is 100 ℃, and the temperature is kept for 3min; raising the temperature to 260 ℃ at a speed of 8 ℃/min, and keeping for 10min;
mass spectrometry conditions: transmission line temperature: 280 ℃; ionization mode: an electron bombardment source; ionization energy: 70eV; ion source temperature: 230 ℃; solvent delay: 8min; the measurement method comprises the following steps: the ion monitoring mode is selected for scanning.
Preferably, the variety of the tobacco is safflower Dajinyuan.
A tobacco mutant created by a method for knocking out genes related to tobacco nicotine metabolism by using a CRISPR/Cas9 system.
Application of a method for knocking out genes related to tobacco nicotine metabolism by using CRISPR/Cas9 system in breeding new varieties of low-nicotine tobacco.
The technical scheme of the invention has the following beneficial effects:
the invention constructs a CRISPR/Cas9 editing vector for knocking out the NtLNP2 gene by a CRISPR/Cas9 mediated gene editing technology, and obtains a safflower Dajinyuan editing plant with the NtLNP2 gene knocked out after editing material creation and molecular detection and identification.
According to the tobacco nicotine metabolism related gene NtLNP2 provided by the invention, through gas chromatography-mass spectrometry combined detection, the leaf nicotine content of the NtLNP2 gene knockout editing plant in the bud period is obviously lower than that of a control plant.
In conclusion, the CRISPR/Cas9 mediated gene editing technology is utilized to knock out the NtLNP2 gene to obtain editing materials with obviously reduced nicotine content, and genetic materials and theoretical basis are provided for the function research of the nicotine metabolic genes of tobacco and the directional improvement of new varieties of low-nicotine tobacco with regulated and controlled nicotine content.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description, serve to explain the principles of the invention.
FIG. 1 is a comparison of the present invention's nicotine content at the bud phase of the edited plants versus the control (unedited) plants.
Detailed Description
Various exemplary embodiments of the present invention will now be described in detail with reference to the accompanying drawings. It should be noted that: the relative arrangement of the components and steps, numerical expressions and numerical values set forth in these embodiments do not limit the scope of the present invention unless it is specifically stated otherwise.
All experimental methods used in the following examples are conventional methods unless otherwise specified. Materials, reagents and the like used in the following examples were commercially available unless otherwise specified.
EXAMPLE 1 acquisition of the NtLNP2 Gene
The method comprises the steps of (1) taking a cultivar tobacco safflower large Jin Yuangen as an experimental material, extracting total RNA of tobacco roots by using an RNA extraction kit, and carrying out reverse transcription to obtain cDNA for later use:
extracting total RNA of tobacco according to the instruction of the plant RNA extraction kit.
1 μg total RNA extracted from leaf for reverse transcription was as follows:
Total RNA 1μg;
Oligo(dT)(10μM) 1.5μL;
ddH 2 O up to 15μL;
mixing the above systems, placing in PCR, maintaining at 70deg.C for 5min, removing, immediately placing on ice for 5min, and adding the following reagents:
placing the above system into a PCR instrument, keeping temperature at 42deg.C for 65min, 65deg.C for 10min, and 4deg.C, and storing in a refrigerator at-20deg.C.
By a homology comparison method, referring to the sequence of the Arabidopsis gene and the sequence of the known tobacco part gene, the amplification primer sequence is designed as follows:
F:5’-ATGTTTCCGCTCATAATTCTG-3’(SEQ ID No.3);
R:5’-TCATTCACTGCTATACTTGTGC-3’(SEQ ID No.4)。
PCR amplification was performed using the cDNA prepared as described above as a template and the above primers:
amplification system (50 μl):
and (3) carrying out PCR amplification after uniformly mixing and centrifuging, wherein the PCR reaction conditions are as follows: 30 cycles of 95℃10sec,52℃30sec,72℃2 min; 72 ℃ for 10min; hold at 25 ℃.
And (3) purifying and sequencing the amplified product to obtain a gene NtLNP2 sequence related to nicotine metabolism of the tobacco, wherein the base sequence of the gene is shown as SEQ ID No.1 and comprises 1506 bases. After the gene sequence is translated, the coded protein sequence is shown as SEQ ID No.2, and the coded protein sequence totally comprises 501 amino acid residues, and further comparative analysis shows that the protein contains a sequence with high homology and is highly conserved.
EXAMPLE 2 construction of expression vectors
The present invention further constructs a CRISPR/Cas9 vector using the nicotine metabolism related gene NtLNP2 obtained in example 1.
(1) Design and synthesis of sgRNA sequence of NtLNP2 gene:
the on-line software CRISPR-P2.0 (http:// cbi. Hzau. Edu. Cn/CRISPR /) is used for designing the sgRNA guide sequence, and the guide sequence with higher score and positioned at the proper position of the NtLNP2 gene sequence is selected. The sgRNA sequences selected in this application are: GAGACCTGCAGATCTACCCGCGG (SEQ ID No. 5).
(2) Forward and reverse primers of sgRNA sequences were designed and submitted to synthesis by design company: the upstream primer sgRNA-F: GATTGGAGACCTGCAGATCTACCCG (SEQ ID No. 6) and the downstream primer sgRNA-R: AAACCGGGTAGATCTGCAGGTCTCC (SEQ ID No. 7);
(3) Primer annealing: the synthesized target sequence primers (upstream primer and downstream primer) were sterilized with ddH 2 O is diluted to 100 ng/. Mu.L, then 5. Mu.L of each of the upstream and downstream primers is taken and mixed into a PCR tube uniformly, and the mixture is placed on a PCR instrument for annealing, so that the upstream and downstream Oligo single chains are annealed to form double chains.
The annealing procedure of the PCR instrument is as follows: 95℃for 2min, -0.1 ℃/8s, annealed to 25℃and the annealed product diluted to 10 ng/. Mu.L with 90. Mu.L sterile water.
(4) Enzyme digestion and ligation
a. The CRISPR/Cas9 vector, port-Cas 9 (supplied by university of southwest) was digested with restriction enzyme BsaI-HF.
Enzyme cleavage System (50. Mu.L):
and (3) performing enzyme digestion at 37 ℃ overnight, performing agarose gel electrophoresis at 1.5%, cutting a target fragment strip, and recovering a framework fragment by using a gel recovery kit.
b. Connection
And (3) connecting the double-chain product formed by annealing with the carrier framework which is cut by the enzyme.
Ligation system (10 μl):
the connection conditions are as follows: the connection was carried out at 16℃for 2 hours.
(5) Transformation of E.coli:
a. Trans-T1 competent cells were removed from-80℃and frozen and thawed on ice, and divided into 50. Mu.L/serving;
b. after the competent cells are melted, 10 mu L of the connection product is added into the competent cells, and the mixture is gently mixed and ice-bathed for 10min;
c. after ice bath, placing the mixture into a water bath kettle at 42 ℃ for heat shock for 90s, and rapidly placing the competence back on ice for standing for 2min.
d. mu.L of the transformation product was uniformly spread on LB solid medium containing 16mg/L kanamycin, and cultured in a bacterial incubator at 37℃for 12 hours.
(6) Positive clone screening:
a. when the flat plate grows out of the monoclonal, E.coli monoclonal is selected and put into a kanamycin LB liquid culture medium containing 50mg/L, and shaking is carried out on a shaking table at 37 ℃ overnight;
b. taking part of bacterial liquid to carry out bacterial liquid PCR, and detecting whether positive cloning exists through nucleic acid electrophoresis;
c. and extracting the escherichia coli plasmid from the remaining part of the bacterial liquid which is detected to be positive clone. The plasmid was sent to Nostoc origin for sequencing to confirm the correctness of the positive clones.
EXAMPLE 3 transformation of Agrobacterium
The CRISPR/Cas9-NtLNP2 editing vector plasmid constructed in the previous step is used for genetic transformation and tissue culture by taking safflower Dajinyuan as an example to obtain a plant with the gene NtLNP2 related to tobacco nicotine metabolism knocked out and edited, and the related experimental process is briefly described as follows.
And (3) after the surfaces of the tobacco seeds are disinfected, dibbling the tobacco seeds on an MS culture medium, growing until 4 cotyledons (15-20 d) are grown, transferring the cotyledons into a culture bottle containing an MS solid culture medium, and continuously culturing for 35-40d at the temperature of 25+/-1 ℃ under the condition that the illumination intensity is 30-50 mu mol/(m 2 s) and the illumination time is 16h/d for standby.
The plasmid with correct sequence is transformed into agrobacterium, and the specific steps are as follows:
(1) LBA4404 stored at-80℃was removed and competent Agrobacterium cells were electrotransformed and frozen and thawed on ice.
(2) When the competence was just thawed, 2 μl of CRISPR/Cas9-NtLNP2 editing vector plasmid was added, mixed well and placed on ice.
(3) Transferring the uniformly mixed competence into a precooled electric rotating cup, placing the electric rotating cup into an electric rotating instrument for conversion, adding 1mL of YEB liquid culture medium and conversion liquid for mixing after conversion is finished, and placing the mixture into a shaking table at 28 ℃ for culturing at 200rpm for 1.5-2h.
(4) The medium was centrifuged at 8,000rpm, the supernatant was discarded, and 200. Mu.L of YEB liquid medium was used to suspend the cells, which were spread on YEB solid medium containing 50mg/L rifampicin, 50mg/L streptomycin and 50mg/L kanamycin, and inverted dark culture was performed at 28℃for 2-3d.
EXAMPLE 4 infection of callus
(1) Square leaf discs with side length of 1cm were made in an ultra clean bench, and agrobacterium colony-forming suspension (OD) containing CRISPR/Cas9-NtLNP2 editing vector was prepared with MS liquid 600 =0.6-0.8)。
(2) And soaking and infecting tobacco leaf discs for 10min by using suspension agrobacterium liquid.
(3) The leaf discs were placed on MS solid medium containing 2.0mg/L NAA+0.5 mg/L6-BA, at 28℃in the dark, and co-cultured for 3d.
(4) Subculturing was performed and placed on MS solid medium containing 2.0mg/L NAA+0.5 mg/L6-BA+250 mg/L Cb+50mg/L Kan.
The culture conditions are as follows: culturing at 28deg.C for 16h/d with light intensity of 30-50 μmol/(m2.s), culturing at 25deg.C in dark for 8h/d, culturing for 45-60d until differentiation bud forms, and changing differentiation culture medium for 3-4 times every 7-10 d; culturing until differentiation buds are formed; cutting off the callus formed by the existing differentiation buds, placing the callus on an MS culture medium containing 500mg/L carbenicillin and 50mg/L kanamycin for culture, and culturing for 8-14 days when the differentiation buds on the callus grow to 2-4cm high under the condition consistent with the differentiation culture condition; rooting and culturing regenerated plants, cutting off differentiated buds, inserting the cut off differentiated buds into an MS culture medium containing 500mg/L of carbenicillin and 50mg/L of kanamycin for rooting and culturing, wherein the culture conditions are consistent with the differentiation culture conditions, culturing for 20-30d, regenerating and transplanting the cut off differentiated buds to a flowerpot for culturing, sampling leaves of the transformed plants, carrying out molecular detection on the leaves of the transformed plants, determining to obtain NtLNP2 gene edited plants, and then harvesting to obtain T0 generation edited plant seeds.
And (3) carrying out selfing homozygous propagation on the T0 generation seeds according to 23 times, sampling the leaves of a single plant when the plants grow to 5-6 leaves, carrying out molecular detection on the large gene, determining that the plants subjected to homozygous editing of the NtLNP2 genes are obtained, and then carrying out seed collection to obtain the T1 generation seeds subjected to homozygous editing of the NtLNP2 genes.
Example 5GC-MS detection
And (3) carrying out seed collection by using the plant which is determined to be homozygous and knocked out by the molecular detection in the embodiment 4 to obtain the homozygous editing material of the gene. Then, GC-MS is used for detecting the nicotine content of leaves in the bud period of the homozygous knockout material of the NtLNP2 gene.
Selecting tobacco plants in a bud period, collecting 5 control (unedited) tobacco plant samples, and collecting leaves at the same leaf position; selecting a tobacco plant in a bud period, and collecting tobacco plant samples of 5 plants homozygous edited by the NtLNP2 gene; removing main ribs of the leaves, wrapping tinfoil paper with liquid nitrogen, preserving and transporting, preserving at ultralow temperature (-70 ℃) in a laboratory, freeze-drying, grinding and sieving.
Weighing 0.2g of sample in a 15mL centrifuge tube to be accurate to 0.1mg, adding 2.0mL of 5% sodium hydroxide solution, respectively adding 0.05mL of internal standard solution A (dimethyl quinoline solution, methanol preparation, methylene dichloride dilution to 1.0 mg/mL) and internal standard solution B (2, 2' -bipyridine-d 2 solution, methanol preparation, methylene dichloride dilution to 0.5 mg/mL), shaking and mixing uniformly, standing for 20min, adding 10.0mL of extraction solution (mixing methylene dichloride and methanol according to the volume ratio of 4:1), sealing, shaking and extracting at the speed of 2000r/min for 40min, centrifuging for 8min, transferring the lower organic phase into a chromatographic bottle, and performing GC-MS analysis.
The gas chromatography reference conditions were: chromatographic column: DB-35MS or equivalent column effect capillary chromatographic column, the specification is: 30mm (length) ×0.25mm (inner diameter) ×0.25m (film thickness); sample inlet temperature: 250 ℃; column flow rate: 1.0mL/min; nicotine sample injection volume: 1.0L, split sample introduction, and split ratio of 40:1; other alkaloid sample injection volumes: 2.0L, split sample introduction, wherein the split ratio is 10:1; heating program: the initial temperature is 100 ℃, and the temperature is kept for 3min; raising the temperature to 260 ℃ at a rate of 8 ℃/min and keeping the temperature for 10min.
Mass spectrometry reference conditions: transmission line temperature: 280 ℃; ionization mode: an electron bombardment source (EI); ionization energy: 70eV; ion source temperature: 230 ℃; solvent delay: 8min; the measurement method comprises the following steps: ion monitoring mode (SIM) scanning is selected.
Comparison of leaf nicotine content at the bud phase of control (unedited) and NtLNP2 gene homozygous edited tobacco plants (results are shown in fig. 1).
The results show that: the leaf nicotine content of the NtLNP2 gene knockout editing plant in the bud phase is obviously lower than that of a control plant through the detection of gas chromatography-mass spectrometry (GC-MS). The method provides genetic materials and theoretical basis for the function research of the nicotine metabolic gene of the tobacco and the cultivation research of new varieties of low-nicotine tobacco.
Although the present invention has been described with reference to the above embodiments, it should be understood that the present invention is not limited thereto, and that various changes and modifications may be made by those skilled in the art without departing from the spirit and scope of the present invention, and the scope of the present invention is defined by the appended claims and their equivalents.
Sequence listing
<110> Yunnan Zhongyan industry Limited liability company
<120> a gene related to nicotine metabolism in tobacco and use thereof
<130> WPC213278
<141> 2021-11-22
<160> 7
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1680
<212> DNA
<213> Artificial sequence (NtLNP 2)
<400> 1
atgtttccgc tcataattct gatcagcttt tcacttgctt ccttgtctga aactgctact 60
ggagctgtta caaatctttc agcctgctta atcaaccaca atgtccataa cttctctatt 120
taccccacaa gtagaaatta ctttaacttg ctccacttct cccttcaaaa tcttcgcttt 180
gctgcacctt tcatgccgaa accaaccttc attatcctac caagcagtaa ggaggagctc 240
gtgagcacca ttttttgttg cagaaaagca tcttatgaaa tcagagtaag gtgcggcgga 300
cacagttacg aaggaacttc ttacgtttcc tttgacgctt ctccattcgt gatcgttgac 360
ttgatgaaat tagacgacgt ttcagtagat ttggattctg aaacagcttg ggctcagggc 420
ggcgcaacaa ttggccaaat ttattatgcc attgccaagg taagtgacgt tcatgcattt 480
tcagcaggtt cgggaccaac agtaggatct ggaggtcata tttcaggtgg tggatttgga 540
cttttatcta gaaaattcgg acttgctgct gataatgtcg ttgatgctct tcttattgat 600
gctgatggac ggttattaga ccgaaaagcc atgggcgaag acgtgttttg ggcaatcaga 660
ggtggcggcg gtggaaattg gggcattgtt tatgcctgga aaattcgatt actcaaagtg 720
cctaaaatcg taacaacttg tatgatctat aggcctggat ccaaacaata cgtggctcaa 780
atacttgaga aatggcaaat agttactcca aatttggtcg atgattttac tctaggagta 840
ctgctgagac ctgcagatct acccgcggat atgaaatatg gtaatactac tcctattgaa 900
atatttcccc aattcaatgc actttatttg ggtccaaaaa ctgaagttct ttccatatcg 960
aatgagacat ttccggagct aggcgttaag aatgatgagt gcaaggaaat gacttgggta 1020
gagtcagcac ttttcttctc cgaattagct gacgttaacg ggaactcgac tggtgatatc 1080
tcccgtctga aagaacgtta catggacgga aaaggttttt tcaaaggcaa aacggactac 1140
gtgaagaagc cagtttcaat ggatgggatg ctaacatttc ttgtggaact cgagaaaaac 1200
ccgaagggat atcttgtctt tgatccttat ggcggagcca tggacaagat tagtgatcaa 1260
gctattgctt tccctcatag aaaaggtaac cttttcgcga ttcagtatct agcacagtgg 1320
aatgaagagg acgattacat gagcgacgtt tacatggagt ggataagagg attttacaat 1380
acaatgacgc cctttgtttc aagctcgcca aggggagctt atatcaacta cttggatatg 1440
gatcttggag tgaatatggt cgacgactac ttattgcgaa atgctagtag cagtagtcct 1500
tcttcctctg ttgatgctgt ggagagagct agagcgtggg gtgagatgta tttcttgcat 1560
aactatgata ggttggttaa agctaagaca caaattgatc cactaaatgt ttttcgacat 1620
gaacagagta ttcctcctat gcttggttca acgcaagagc acaagtatag cagtgaatga 1680
<210> 2
<211> 558
<212> PRT
<213> Artificial sequence (Artificial Sequence)
<400> 2
Met Phe Pro Leu Ile Ile Leu Ile Ser Phe Ser Leu Ala Ser Leu Ser
1 5 10 15
Glu Thr Ala Thr Gly Ala Val Thr Asn Leu Ser Ala Cys Leu Ile Asn
20 25 30
His Asn Val His Asn Phe Ser Ile Tyr Pro Thr Ser Arg Asn Tyr Phe
35 40 45
Asn Leu Leu His Phe Ser Leu Gln Asn Leu Arg Phe Ala Ala Pro Phe
50 55 60
Met Pro Lys Pro Thr Phe Ile Ile Leu Pro Ser Ser Lys Glu Glu Leu
65 70 75 80
Val Ser Thr Ile Phe Cys Cys Arg Lys Ala Ser Tyr Glu Ile Arg Val
85 90 95
Arg Cys Gly Gly His Ser Tyr Glu Gly Thr Ser Tyr Val Ser Phe Asp
100 105 110
Ala Ser Pro Phe Val Ile Val Asp Leu Met Lys Leu Asp Asp Val Ser
115 120 125
Val Asp Leu Asp Ser Glu Thr Ala Trp Ala Gln Gly Gly Ala Thr Ile
130 135 140
Gly Gln Ile Tyr Tyr Ala Ile Ala Lys Val Ser Asp Val His Ala Phe
145 150 155 160
Ser Ala Gly Ser Gly Pro Thr Val Gly Ser Gly Gly His Ile Ser Gly
165 170 175
Gly Gly Phe Gly Leu Leu Ser Arg Lys Phe Gly Leu Ala Ala Asp Asn
180 185 190
Val Val Asp Ala Leu Leu Ile Asp Ala Asp Gly Arg Leu Leu Asp Arg
195 200 205
Lys Ala Met Gly Glu Asp Val Phe Trp Ala Ile Arg Gly Gly Gly Gly
210 215 220
Gly Asn Trp Gly Ile Val Tyr Ala Trp Lys Ile Arg Leu Leu Lys Val
225 230 235 240
Lys Ile Val Thr Thr Cys Met Ile Tyr Arg Pro Gly Ser Lys Gln Tyr
245 250 255
Val Ala Gln Ile Leu Glu Lys Trp Gln Ile Val Thr Pro Asn Leu Val
260 265 270
Asp Asp Phe Thr Leu Gly Val Leu Leu Arg Pro Ala Asp Leu Pro Ala
275 280 285
Asp Met Lys Tyr Gly Asn Thr Thr Pro Ile Glu Ile Phe Pro Gln Phe
290 295 300
Asn Ala Leu Tyr Leu Gly Pro Lys Thr Glu Val Leu Ser Ile Ser Asn
305 310 315 320
Glu Thr Phe Pro Glu Leu Gly Val Lys Asn Asp Glu Cys Lys Glu Met
325 330 335
Thr Trp Val Glu Ser Ala Leu Phe Phe Ser Glu Leu Ala Asp Val Asn
340 345 350
Gly Asn Ser Thr Gly Asp Ile Ser Arg Leu Lys Glu Arg Tyr Met Asp
355 360 365
Gly Lys Gly Phe Phe Lys Gly Lys Thr Asp Tyr Val Lys Lys Pro Val
370 375 380
Ser Met Asp Gly Met Leu Thr Phe Leu Val Glu Leu Glu Lys Asn Pro
385 390 395 400
Lys Gly Tyr Leu Val Phe Asp Pro Tyr Gly Gly Ala Met Asp Lys Ile
405 410 415
Ser Asp Gln Ala Ile Ala Phe Pro His Arg Lys Gly Asn Leu Phe Ala
420 425 430
Ile Gln Tyr Leu Ala Gln Trp Asn Glu Glu Asp Asp Tyr Met Ser Asp
435 440 445
Val Tyr Met Glu Trp Ile Arg Gly Phe Tyr Asn Thr Met Thr Pro Phe
450 455 460
Val Ser Ser Ser Pro Arg Gly Ala Tyr Ile Asn Tyr Leu Asp Met Asp
465 470 475 480
Leu Gly Val Asn Met Val Asp Asp Tyr Leu Leu Arg Asn Ala Ser Ser
485 490 495
Ser Ser Pro Ser Ser Ser Val Asp Ala Val Glu Arg Ala Arg Ala Trp
500 505 510
Gly Glu Met Tyr Phe Leu His Asn Tyr Asp Arg Leu Val Lys Ala Lys
515 520 525
Thr Gln Ile Asp Pro Leu Asn Val Phe Arg His Glu Gln Ser Ile Pro
530 535 540
Pro Met Leu Gly Ser Thr Gln Glu His Lys Tyr Ser Ser Glu
545 550 555
<210> 3
<211> 21
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 3
atgtttccgc tcataattct g 21
<210> 4
<211> 22
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 4
tcattcactg ctatacttgt gc 22
<210> 5
<211> 23
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 5
gagacctgca gatctacccg cgg 23
<210> 6
<211> 25
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 6
gattggagac ctgcagatct acccg 25
<210> 7
<211> 25
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 7
aaaccgggta gatctgcagg tctcc 25
Claims (4)
1. The application of the gene related to the tobacco nicotine metabolism in reducing the leaf nicotine content of the tobacco in the bud stage is characterized in that the gene related to the tobacco nicotine metabolism is a NtLNP2 gene, the sequence of the gene is SEQ ID No.1, and the leaf nicotine content of a plant in the bud stage is obviously lower than that of a control plant by knocked-out and edited by the NtLNP2 gene;
the method for knocking out the gene related to tobacco nicotine metabolism by using the CRISPR/Cas9 system comprises the following steps:
(1) Designing a sgRNA guide sequence and constructing a sgRNA expression vector;
(2) Introducing an expression vector into agrobacterium;
(3) Infection of callus;
(4) Detecting the nicotine content of leaves in the bud period of the NtLNP2 gene homozygous knockout material by using GC-MS;
the CRISPR/Cas9 system adopts a sgRNA sequence of GAGACCTGCAGATCTACCCGCGG, and the sgRNA sequence adopts a primer sequence of:
the upstream primer sgRNA-F: GATTGGAGACCTGCAGATCTACCCG;
the downstream primer sgRNA-R: AAACCGGGTAGATCTGCAGGTCTCC;
the variety of the tobacco is safflower Dajinyuan.
2. The use according to claim 1, wherein step (1) is specifically:
designing an sgRNA guide sequence, annealing an upstream primer sgRNA-F and a downstream primer sgRNA-R to form a double chain, and performing restriction enzyme digestion on a CRISPR/Cas9 vector pORE-Cas9 by using restriction enzyme BsaI-HF; connecting the double-stranded product formed by annealing with the carrier skeleton cut by enzyme by using T4 ligase; and (3) converting the connection product into competent cells of escherichia coli, detecting to obtain positive clones, and extracting the recombinant plasmid to obtain the CRISPR-Cas9 expression vector.
3. The use according to claim 1, wherein step (3) is specifically:
and soaking the infected tobacco leaf disc with agrobacterium tumefaciens LBA4404 bacterial liquid carrying the CRISPR/Cas9-sgRNA expression vector, and obtaining the T0 generation editing plant seeds and the T1 generation seeds.
4. The use according to claim 1, wherein the chromatographic conditions in step (4) are:
the gas chromatography conditions were: chromatographic column: DB-35MS; the specification is as follows: 30mm×0.25mm ×0.25m; sample introduction temperature: 250. the temperature is lower than the temperature; column flow rate: 1.0mL/min; nicotine sample injection volume: 1.0L, split-flow sample introduction, wherein the split-flow ratio is 40:1; other alkaloid sample injection volumes: 2.0L, split-flow sample introduction, wherein the split-flow ratio is 10:1; heating program: the initial temperature is 100 ℃, and the temperature is kept for 3min; raising the temperature to 260 ℃ at a speed of 8 ℃/min, and keeping for 10min;
mass spectrometry conditions: transmission line temperature: 280. the temperature is lower than the temperature; ionization mode: an electron bombardment source; ionization energy: 70eV; ion source temperature: 230. the temperature is lower than the temperature; solvent delay: 8min; the measurement method comprises the following steps: the ion monitoring mode is selected for scanning.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111388043.8A CN114085845B (en) | 2021-11-22 | 2021-11-22 | Tobacco nicotine metabolism related gene and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111388043.8A CN114085845B (en) | 2021-11-22 | 2021-11-22 | Tobacco nicotine metabolism related gene and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114085845A CN114085845A (en) | 2022-02-25 |
CN114085845B true CN114085845B (en) | 2024-03-08 |
Family
ID=80302925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111388043.8A Active CN114085845B (en) | 2021-11-22 | 2021-11-22 | Tobacco nicotine metabolism related gene and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114085845B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101155920A (en) * | 2005-02-28 | 2008-04-02 | 奈良先端科学技术大学院大学 | Reducing levels of nicotinic alkaloids in plants |
CN107613762A (en) * | 2015-05-05 | 2018-01-19 | 北卡罗莱纳州立大学 | Reduce the method and composition of the tobacco-specific nitrosamines NNK in tobacco |
CN112702927A (en) * | 2018-07-27 | 2021-04-23 | 卡巴斯有限责任公司 | Method and product for promoting smoker to switch to tobacco heating product or electronic cigarette |
-
2021
- 2021-11-22 CN CN202111388043.8A patent/CN114085845B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101155920A (en) * | 2005-02-28 | 2008-04-02 | 奈良先端科学技术大学院大学 | Reducing levels of nicotinic alkaloids in plants |
CN107613762A (en) * | 2015-05-05 | 2018-01-19 | 北卡罗莱纳州立大学 | Reduce the method and composition of the tobacco-specific nitrosamines NNK in tobacco |
CN112702927A (en) * | 2018-07-27 | 2021-04-23 | 卡巴斯有限责任公司 | Method and product for promoting smoker to switch to tobacco heating product or electronic cigarette |
Non-Patent Citations (3)
Title |
---|
Kajikawa M等.Nicotiana tabacum reticuline oxidase-like (LOC107791775),mRNA,NCBI Reference Sequence: NM_001325524.1,1792bp mRNA linear.《NCBI genbank》.2016,第1-2页. * |
Nicotiana tabacum reticuline oxidase-like (LOC107791775),mRNA,NCBI Reference Sequence: NM_001325524.1,1792bp mRNA linear;Kajikawa M等;《NCBI genbank》;第1-2页 * |
基于CRISPR/Cas9技术的烟草烟碱相关基因敲除及功能研究;冯吉等;《中国烟草科学》;第第42卷卷(第第2期期);第84-90页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114085845A (en) | 2022-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113999857B (en) | Gene related to synthesis regulation of nicotine in tobacco and application thereof | |
CN110257421B (en) | Construction method and application of brassica napus gene mutant PTG8 | |
CN113980978B (en) | Tobacco nicotine transporter related gene and application thereof | |
CN114438105B (en) | Tobacco NtMLO6-1 gene and knockout method and application thereof | |
CN114085845B (en) | Tobacco nicotine metabolism related gene and application thereof | |
CN114106121B (en) | FvGR3 protein, and coding gene and application thereof | |
CN114657157B (en) | Application of ZmD protein in regulation of corn plant height | |
CN107557384B (en) | Genetic transformation system for inducing plant dwarfing and construction and application thereof | |
CN115058433B (en) | Tobacco leaf yellowing regulatory gene NtMYB2, protein and application thereof | |
CN114507688A (en) | Application of tobacco NtCNGC4 gene in preparation of tobacco mutant material for regulating plant height and leaf amino acid content | |
CN113943740A (en) | NtCHA1 gene capable of regulating and controlling potassium content of tobacco leaf and application thereof | |
CN114574499A (en) | Application of OsREP3 gene in controlling drought resistance of rice | |
CN114410677A (en) | Method for creating low-nicotine tobacco mutant by using CRISPR/Cas9 to knock out NtBBBLs and application | |
CN114540368B (en) | Application and method of tobacco amino acid transporter related gene NtLHT1 | |
CN114426973B (en) | Tobacco guide protein related gene NtImpα4 and application thereof | |
CN114836430B (en) | Application of tobacco ABA receptor protein gene NtPYL6 in regulation and control of tobacco plant height and leaf rutin content | |
CN114807081B (en) | Tobacco glutathione transfer related gene and application thereof | |
CN114085851B (en) | Gene for regulating and controlling tobacco flowering time and application thereof | |
CN116004646B (en) | Tobacco NtSWEET gene and application thereof | |
CN115704035B (en) | Tobacco NtDSR2 gene and application thereof | |
CN115896168A (en) | Method for rapidly obtaining and cultivating nicotine transformed tobacco plant and application | |
CN116217685A (en) | Method for obtaining tobacco with leaf shape changed and low nicotine content by knocking out tobacco NtLNP1 gene and application | |
CN115704036B (en) | Tobacco NtDSR1 gene and application thereof | |
CN116004647B (en) | Tobacco NtSWEET gene and application thereof | |
CN117024541A (en) | Tobacco iron redox protein gene Ntab0899580 and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |